Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
Caribou Biosciences announced alignment with the FDA on the pivotal Phase 3 ANTLER-3 trial design for vispa-cel, de-risking its lead asset program in 2L large B cell lymphoma. Financial results show disciplined cost management, with R&D expenses dropping 42% year-over-year to $20.6 million, extending the cash runway into the second half of 2027.
Key figures
- Revenue
- 2397000
- Net loss
- 25085000
- Ga expenses
- 8066000
- Rd expenses
- 20611000
- Cash and securities
- 118627000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.